Nanexa’s Phase I trial of NEX-22 in type 2- diabetes progresses with next dose group according to plan

Nanexa AB today announces that the company's Phase 1 study for type 2 diabetes continues dose escalation according to plan with their long-acting depot formulation of the GLP-1 analog liraglutide.

The appointed dose escalation committee of the study has been able to make the judgement to continue dosing in the next treatment group, based on data from patients in the first treatment group. “We are pleased to have the first clinical results for NEX-22 in patients with type 2 diabetes clearly confirming a prolonged release with an extended pharmacokinetic profile while the safety profile is observed with only mild injection site reactions,” says David Westberg, CEO of Nanexa. “We will continue generating important information for the progress of the NEX-22 project, but also for opening up opportunities for other GLP-1 drugs with the PharmaShell® technology”. 
In the study, the long-acting formulation of NEX-22 is administered by subcutaneous injection. The study is designed to include several consecutive groups with escalating doses aimed at evaluating the pharmacokinetic profile, safety and tolerability of different doses. 
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of drugs for the treatment of type 2 diabetes and obesity. Liraglutide is a GLP-1 analog in the marketed products Victoza and Saxenda given as daily injections.